October 24, 2026 — In the pursuit of more effective therapeutic options for patients battling advanced or metastatic biliary tract cancer (BTC), researchers have long sought to move beyond the limitations of standard chemotherapy. Data presented at the European Society for Medical Oncology (ESMO) annual congress in Madrid and simultaneously published in the Journal of Clinical Oncology suggests a significant step forward, albeit one complicated by nuanced survival data.
The COMPANION-002 trial, a phase II/III randomized study, evaluated the efficacy of the novel bispecific antibody tovecimig in combination with paclitaxel. While the doublet demonstrated a clear superiority in response rates and progression-free survival (PFS) compared to paclitaxel monotherapy, the trial failed to meet its primary objective regarding overall survival (OS), likely due to the confounding influence of crossover study design.
The Challenge of Biliary Tract Malignancies
Biliary tract cancers—a group of rare but highly aggressive malignancies including cholangiocarcinoma and gallbladder cancer—represent a significant clinical hurdle. With a median overall survival often hovering around 12 months for advanced-stage disease, the standard of care has historically been limited. As incidence and mortality rates rise globally, the medical community has faced an urgent, unmet need for therapies that can effectively halt progression in the second-line setting, where patients have already failed initial treatment with gemcitabine and cisplatin.
Mechanism and Clinical Rationale
Tovecimig is a first-in-class recombinant bispecific antibody designed to inhibit both VEGF-A and DLL4. By simultaneously targeting these two pathways, the drug aims to disrupt tumor angiogenesis and signaling in a way that traditional single-target agents cannot.
"In early clinical testing, this molecule, as a monotherapy, showed activity in colorectal cancer and gastric cancer," explained Nilofer S. Azad, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Preclinical models and early-phase clinical data provided a compelling rationale for the COMPANION-002 study, suggesting that the addition of tovecimig could sensitize tumors to paclitaxel, creating a potent synergistic effect.
Key Findings: The COMPANION-002 Trial Data
The study enrolled 168 patients who had progressed after one prior line of chemotherapy. These patients were randomized 2:1 to receive either the experimental doublet (tovecimig plus paclitaxel) or paclitaxel alone.
Primary and Secondary Endpoints
The trial successfully met its primary endpoint regarding objective response rate (ORR). Patients treated with the tovecimig doublet achieved an ORR of 18.0%, compared to just 5.3% in the control arm (P=0.0228).
Progression-free survival (PFS), a critical metric for patients with aggressive, symptomatic disease, was also significantly improved. The doublet arm achieved a median PFS of 4.7 months, compared to 2.6 months for those receiving only paclitaxel (HR 0.44, 95% CI 0.30-0.66, P<0.0001).
The Overall Survival Conundrum
Despite the success in ORR and PFS, the overall survival data proved more complex. The median OS was 8.9 months for the combination arm versus 9.4 months for the control arm (HR 1.05, 95% CI 0.7-1.5, P=0.77).
Dr. Azad noted that these findings were likely heavily confounded by the trial’s design, which permitted patients in the control arm to cross over to the experimental treatment upon documentation of disease progression. This allowed 54% of the 57 patients in the paclitaxel-only arm to eventually receive tovecimig. The clinical benefit of this crossover was notable: patients who switched to tovecimig saw a median PFS of 3.5 months, compared to 1.9 months before the crossover (HR 0.40, P=0.0035). Furthermore, a subset analysis showed that those who crossed over achieved a median OS of 12.8 months, versus 6.1 months for those who did not, suggesting that the treatment is indeed life-prolonging when administered.
Safety and Tolerability
The safety profile of the doublet was described as "manageable" and consistent with the toxicities typically associated with VEGF-targeted agents. However, the intensity of side effects warrants clinical attention.
Hypertension and fatigue were the most frequently reported treatment-emergent adverse events (TEAEs), occurring in 69.4% and 66.7% of patients, respectively. High-grade (Grade ≥3) TEAEs were reported in 93.5% of the combination group. Furthermore, the combination arm experienced a higher rate of treatment interruptions and permanent discontinuations compared to the control group. There were six fatal TEAEs in the combination arm, including two cases linked to treatment (septic shock and renal failure/sepsis), highlighting the necessity for careful patient selection and close monitoring in future clinical applications.
Expert Perspectives and Implications
The results have sparked a measured debate among oncology experts regarding how to integrate tovecimig into existing clinical pathways.
The Discussant’s View
Sebastián Mondaca, MD, MBA, of the Pontificia Universidad Católica de Chile, acting as the ESMO invited discussant, acknowledged the importance of the study. "The results are encouraging, given the promising mechanism of action and the low bar that we have in this setting," he noted.
However, Dr. Mondaca emphasized that the data, while scientifically robust, do not necessarily dictate an immediate shift in clinical practice. He argued that the current control arm—paclitaxel monotherapy—might not represent the ideal benchmark. "Ideally, we would like to have a phase III trial with FOLFOX [fluorouracil, leucovorin, and oxaliplatin] as the comparison arm, demonstrating a clear benefit in overall survival," he stated. Despite these reservations, he conceded that given the high unmet need for patients with limited options, a formal review by regulatory guideline committees is essential to determine if this therapy should be offered to specific patient subsets.
Looking Ahead: Regulatory and Clinical Future
The COMPANION-002 trial highlights the ongoing challenge of interpreting clinical trial data when crossover protocols are utilized. While the lack of a clear OS benefit on an intention-to-treat basis is disappointing at first glance, the secondary analyses suggest that tovecimig provides meaningful clinical activity for patients with biliary tract cancer.
The future of tovecimig will likely depend on whether regulators find the PFS improvement and the survival signal in the crossover group sufficient for approval, or if they will demand a subsequent phase III study against a more robust control arm. For now, the oncological community views the results as a "promising strategy" that requires further refinement to optimize the benefit-risk profile for a patient population that remains in dire need of effective second-line therapeutic alternatives.
As clinical research continues to evolve, the focus will likely remain on biomarkers that might predict which patients are most likely to respond to VEGF/DLL4 inhibition, potentially allowing for a more personalized approach to this aggressive disease. For clinicians in the field, the COMPANION-002 trial provides a critical data point in the ongoing effort to transform biliary tract cancer from a rapidly fatal condition into one that can be managed with sustained, effective therapeutic interventions.
